JP2008518936A5 - - Google Patents

Download PDF

Info

Publication number
JP2008518936A5
JP2008518936A5 JP2007539201A JP2007539201A JP2008518936A5 JP 2008518936 A5 JP2008518936 A5 JP 2008518936A5 JP 2007539201 A JP2007539201 A JP 2007539201A JP 2007539201 A JP2007539201 A JP 2007539201A JP 2008518936 A5 JP2008518936 A5 JP 2008518936A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007539201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008518936A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/039091 external-priority patent/WO2006050166A2/en
Publication of JP2008518936A publication Critical patent/JP2008518936A/ja
Publication of JP2008518936A5 publication Critical patent/JP2008518936A5/ja
Pending legal-status Critical Current

Links

JP2007539201A 2004-10-29 2005-10-31 Rsv感染症および関連状態を予防および治療する方法 Pending JP2008518936A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US62382104P 2004-10-29 2004-10-29
US67572405P 2005-04-27 2005-04-27
US68123305P 2005-05-13 2005-05-13
US71871905P 2005-09-21 2005-09-21
US72704305P 2005-10-14 2005-10-14
US72704205P 2005-10-14 2005-10-14
PCT/US2005/039091 WO2006050166A2 (en) 2004-10-29 2005-10-31 Methods of preventing and treating rsv infections and related conditions

Publications (2)

Publication Number Publication Date
JP2008518936A JP2008518936A (ja) 2008-06-05
JP2008518936A5 true JP2008518936A5 (enExample) 2008-12-11

Family

ID=36319691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007539201A Pending JP2008518936A (ja) 2004-10-29 2005-10-31 Rsv感染症および関連状態を予防および治療する方法

Country Status (6)

Country Link
US (3) US20060115485A1 (enExample)
EP (1) EP1812068A4 (enExample)
JP (1) JP2008518936A (enExample)
AU (1) AU2005302453A1 (enExample)
CA (1) CA2585891A1 (enExample)
WO (1) WO2006050166A2 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064751A2 (en) 2000-03-01 2001-09-07 Medimmune, Inc. High potency recombinant antibodies and method for producing them
ATE474854T1 (de) * 2000-01-27 2010-08-15 Medimmune Llc Rsv neutralisierende antikörper mit sehr hohen affinität
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
JP4330532B2 (ja) * 2002-07-18 2009-09-16 株式会社セルフリーサイエンス 単鎖抗体およびその利用
AU2005302453A1 (en) * 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
WO2007079755A1 (en) 2006-01-12 2007-07-19 Janus Beierholm Holding Aps Reimmunization and antibody design
US20090175805A1 (en) * 2006-03-13 2009-07-09 The Trustees Of Columbia University In The City Of New York Neuraminidase Inhibitors and uses thereof
IN2014DN10515A (enExample) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
DK2027158T3 (da) 2006-05-02 2013-01-14 Carviar Aps Metode til immunisering af en fugleart
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
ES2713864T3 (es) 2008-06-05 2019-05-24 Ablynx Nv Secuencias de aminoácidos dirigidas contra proteínas de la envuelta de un virus y polipéptidos que comprenden las mismas para el tratamiento de enfermedades virales
JP2012506705A (ja) 2008-10-27 2012-03-22 キアジェン ゲイサーズバーグ インコーポレイテッド 迅速に結果を得るハイブリッドキャプチャー法による分析およびシステム
US8775090B2 (en) 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
JP2012516158A (ja) * 2009-01-29 2012-07-19 メディミューン,エルエルシー 延長したインビボ半減期を有するヒト抗il−6抗体ならびに腫瘍学、自己免疫疾患、および炎症性疾患の治療におけるそれらの使用
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP2438087B1 (en) 2009-06-05 2017-05-10 Ablynx N.V. Trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
US8840889B2 (en) 2009-08-13 2014-09-23 The Johns Hopkins University Methods of modulating immune function
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US20120263715A1 (en) * 2009-10-28 2012-10-18 Medimmune, Llc Topical Methods Of Treating RSV Infections And Related Conditions
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
KR102568454B1 (ko) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
EP3604330A1 (en) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之FcRn結合域的治療性抗原結合分子
KR20140076593A (ko) 2011-09-30 2014-06-20 추가이 세이야쿠 가부시키가이샤 항원의 소실을 촉진시키는 항원 결합 분자
BR112014013081A2 (pt) 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha veículo contendo fármaco em célula para formação de um complexo imune
JP6226752B2 (ja) 2012-02-09 2017-11-08 中外製薬株式会社 抗体のFc領域改変体
TW202500756A (zh) 2012-02-24 2025-01-01 日商中外製藥股份有限公司 經FcγRIIB促進抗原消失之抗原結合分子
WO2013130773A2 (en) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
CA2933200C (en) * 2014-01-15 2025-05-06 Medimmune Limited RSV-SPECIFIC ANTIBODIES AND THEIR FUNCTIONAL PARTS
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
TWI656133B (zh) 2014-12-19 2019-04-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
AR107078A1 (es) 2015-12-18 2018-03-21 Chugai Pharmaceutical Co Ltd Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR102306744B1 (ko) 2016-06-17 2021-09-28 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
US12211624B2 (en) 2018-06-29 2025-01-28 Health Solutions Research, Inc. Methods and systems of predicting PPE needs
US20220027813A1 (en) * 2017-05-01 2022-01-27 Health Solutions Research, Inc. Risk identification and response for mitigating disease transmission
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
IL322309A (en) 2017-05-24 2025-09-01 Novartis Ag IL2 antibody grafted proteins and methods of use in cancer treatment
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
IL277375B2 (en) 2018-03-15 2025-08-01 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
JP2022502488A (ja) * 2018-09-21 2022-01-11 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 粘液を透過するのを制限するための合成結合剤
KR20210096559A (ko) 2018-11-27 2021-08-05 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 항IL-23p19 항체 및 이의 용도
BR112022012010A2 (pt) 2019-12-18 2022-08-30 Hoffmann La Roche Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
JP2023542867A (ja) 2020-09-11 2023-10-12 グリンプス バイオ, インコーポレイテッド 疾患の検出/診断、病期分類、モニタリング及び処置のための生体外でのプロテアーゼ活性検出
JP2024523034A (ja) 2021-06-18 2024-06-25 エフ. ホフマン-ラ ロシュ アーゲー 二重特異性抗ccl2抗体

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517304A (en) * 1980-07-01 1985-05-14 National Research Development Corporation Production of viral antigens
WO1982003089A1 (en) * 1981-03-06 1982-09-16 Lennox Edwin Samuel Monoclonal antibody
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US5340926A (en) * 1983-03-25 1994-08-23 Celltech, Limited Process for the recovery of recombinantly produced protein from insoluble aggregate
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US5332805A (en) * 1984-02-03 1994-07-26 Celltech Limited Process for the recovery of recombinantly produced chymosin from insoluble aggregate
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
FR2590674B1 (fr) * 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
US4717766A (en) * 1986-01-27 1988-01-05 Miles Laboratories, Inc. Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin
US4659563A (en) * 1986-01-27 1987-04-21 Miles Laboratories, Inc. High titer anti-respiratory syncytial virus intravenous immune globulin
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
GB8719041D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
DE3878468T2 (de) * 1987-12-23 1993-06-09 Upjohn Co Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.
US5183657A (en) * 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
US5137804A (en) * 1988-05-10 1992-08-11 E. I. Du Pont De Nemours And Company Assay device and immunoassay
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5518725A (en) * 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
CA2071867A1 (en) * 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5279935A (en) * 1990-03-01 1994-01-18 Becton, Dickinson And Company Method of immunossay including deactivation of endogenous alkaline phosphatase
AU637914B2 (en) * 1990-05-03 1993-06-10 Systemix, Inc. Human lymphoid tissue in an immunocompromised host
AU668092B2 (en) * 1991-04-22 1996-04-26 Massachusetts Health Research Institute, Inc. Process of screening plasma samples for effective antibody titers against respiratory viruses
CA2109528A1 (en) * 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5240694A (en) * 1991-09-23 1993-08-31 University Of Virginia Combined antiviral and antimediator treatment of common colds
US5418136A (en) * 1991-10-01 1995-05-23 Biostar, Inc. Devices for detection of an analyte based upon light interference
WO1993010460A1 (en) * 1991-11-15 1993-05-27 Cornell Research Foundation, Inc. Indirect immunoassay for dioxinlike compounds
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US20020102257A1 (en) * 1998-09-21 2002-08-01 Leslie Sid Johnson Human-murine chimeric antibodies against respiratory syncytial virus
US5667988A (en) * 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US6685942B1 (en) * 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
AU686113B2 (en) * 1992-09-16 1998-02-05 Scripps Research Institute, The Human neutralizing monoclonal antibodies to respiratory syncytial virus
CA2153661A1 (en) * 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5934272A (en) * 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5424189A (en) * 1993-03-05 1995-06-13 Kansas State University Research Foundation Bovine respiratory syncytial virus detection and primers
NZ269735A (en) * 1993-07-30 1998-01-26 Oravax Inc Monoclonal iga antibody against respiratory syncytial virus (rsv)
US5506209A (en) * 1994-05-26 1996-04-09 Abbott Laboratories Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5538952A (en) * 1994-05-26 1996-07-23 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5747035A (en) * 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6121022A (en) * 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
EP0853487B1 (en) * 1995-09-18 2000-07-05 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
DK0885002T3 (da) * 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6117980A (en) * 1997-02-21 2000-09-12 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6069551A (en) * 1997-05-02 2000-05-30 Therm-O-Disc, Incorporated Thermal switch assembly
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6572856B1 (en) * 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7149773B2 (en) * 1999-07-07 2006-12-12 Medtronic, Inc. System and method of automated invoicing for communications between an implantable medical device and a remote computer system or health care provider
WO2001064751A2 (en) * 2000-03-01 2001-09-07 Medimmune, Inc. High potency recombinant antibodies and method for producing them
US7229619B1 (en) * 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
ATE474854T1 (de) * 2000-01-27 2010-08-15 Medimmune Llc Rsv neutralisierende antikörper mit sehr hohen affinität
WO2001059142A1 (en) * 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
US6565849B2 (en) * 2000-03-02 2003-05-20 Medimmune, Inc. Methods of enhancing activity of vaccines and vaccine compositions
EP2264072A1 (en) * 2000-04-13 2010-12-22 The Rockefeller University Enhancement of antibody-mediated cytotoxicity.
US20020004046A1 (en) * 2000-05-03 2002-01-10 Johnson Leslie S. Combination therapy of respiratory diseases using antibodies
ATE300713T1 (de) * 2000-05-03 2005-08-15 Ipv Inheidener Produktions Und Thermobehälter
ATE457177T1 (de) * 2000-05-03 2010-02-15 Medimmune Llc Kombinationstherapie zur behandlung respiratorischer krankheiten mittels antikörper und anti-entzündungs wirkstoffe
WO2001089562A1 (en) * 2000-05-25 2001-11-29 Medimmune, Inc. F-protein epitope-based vaccine for respiratory syncytial virus infection
WO2002011753A1 (en) * 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
US6565888B1 (en) * 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
EP2412384A1 (en) * 2000-11-28 2012-02-01 MedImmune, LLC Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
PT1355919E (pt) * 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7658921B2 (en) * 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2003256823B9 (en) * 2002-07-25 2009-01-08 Medimmune, Llc Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
US7217798B2 (en) * 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7700720B2 (en) * 2004-09-21 2010-04-20 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
AU2005302453A1 (en) * 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
US8568726B2 (en) * 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule

Similar Documents

Publication Publication Date Title
JP2008518936A5 (enExample)
JP2003525061A5 (enExample)
IL323384A (en) Methods for treating chronic sinusitis with nasal polyps by adding an IL-4R antagonist
JP2006522830A5 (enExample)
JP2010528601A5 (enExample)
JP2024150445A5 (enExample)
JP2009511480A5 (enExample)
JP2011006464A (ja) 喘息の治療における抗−TNFα抗体
KR20140015123A (ko) 페길화된 Aβ FAB
JP2018535650A5 (enExample)
JP2012504955A5 (enExample)
JP2004534513A5 (enExample)
JP2018535948A5 (enExample)
JP2011518886A5 (enExample)
CN116327923A (zh) 生物医药组合物
KR102337599B1 (ko) 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법
RU2007124730A (ru) Способы лечения респираторного заболевания с применением антагонистов рецептора интерлейкина-1 типа 1
RU2765878C2 (ru) Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний
JPWO2019243159A5 (enExample)
JP6640219B2 (ja) Il−20rの拮抗による慢性閉塞性肺疾患の急性増悪の処置
JP2010521139A5 (enExample)
JP2023539047A (ja) 造血幹細胞移植関連血栓性微小血管症(hsct-tma)を処置するための抗c5抗体の用量及び投与
EP4309733A1 (en) Neutralization of acyl-coa binding protein for the treatment of cardiac dysfunction
TWI870471B (zh) 全身性硬化症治療用醫藥組合物
CN115814076A (zh) 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用